Elike Treffers-Westerlaken

The In Vivo Therapeutic Efficacy of the Oncolytic Adenovirus Delta24-RGD Is Mediated by Tumor-Specific Immunity

Anne Kleijn, Jenneke J. Kloezeman, Elike Treffers-Westerlaken et al. · PLoS ONE · 2014 · 70 citations · Full text

Immunology, Vivo Therapeutic Efficacy, Cd4 T Cell Responses +19

Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells

Nadine Pouw, Elike Treffers-Westerlaken, Jaco Kraan et al. · Cancer Immunology Immunotherapy · 2010 · 66 citations · Full text

Inflammation, Cytokine, Cancer Immunosurveillance +8

Recurrence of Melanoma Following T Cell Treatment: Continued Antigen Expression in a Tumor That Evades T Cell Recruitment

Trudy Straetemans, Cor Berrevoets, Miriam Coccoris et al. · Molecular Therapy · 2014 · 29 citations · Full text

TCR gene-engineered T cell: Limited T cell activation and combined use of IL-15 and IL-21 ensure minimal differentiation and maximal antigen-specificity

Nadine Pouw, Elike Treffers-Westerlaken, Anna Mondino et al. · Molecular Immunology · 2010 · 19 citations

Autoimmune Disease, Maximal Antigen-specificity, Adaptive Immune System +9

The therapeutic efficacy of the oncolytic virus Delta24-RGD in a murine glioma model depends primarily on antitumor immunity

Anne Kleijn, Jenneke J. Kloezeman, Elike Treffers-Westerlaken et al. · OncoImmunology · 2014 · 15 citations · Full text

Cancer Immunosurveillance, Therapeutic Effect, Oncolytic Viruses +15